12.62 USD
-0.04 (-0.32%)
12.62 USD
0 (0%)
Overall IART gets a fundamental rating of 4 out of 10. We evaluated IART against 186 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of IART while its profitability can be described as average. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
Of the past 5 years IART 4 years were profitable.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART's Return On Assets of -13.58% is in line compared to the rest of the industry. IART outperforms 58.60% of its industry peers.
The Return On Equity of IART (-47.74%) is comparable to the rest of the industry.
The Return On Invested Capital of IART (4.27%) is better than 74.73% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IART is below the industry average of 8.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a better Operating Margin (10.22%) than 79.03% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 57.21%, IART is in line with its industry, outperforming 56.99% of the companies in the same industry.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
IART has less shares outstanding than it did 5 years ago.
IART has a worse debt/assets ratio than last year.
2.2 Solvency
IART has an Altman-Z score of 1.25. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART has a Altman-Z score of 1.25. This is comparable to the rest of the industry: IART outperforms 53.23% of its industry peers.
A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.73, IART is doing worse than 81.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.25 |
ROIC/WACC0.76
WACC5.63%
2.3 Liquidity
A Current Ratio of 3.14 indicates that IART has no problem at all paying its short term obligations.
The Current ratio of IART (3.14) is comparable to the rest of the industry.
A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
IART has a Quick ratio of 1.80. This is comparable to the rest of the industry: IART outperforms 48.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
The Earnings Per Share has been decreasing by -1.35% on average over the past years.
The Revenue has been growing slightly by 4.99% in the past year.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
The Earnings Per Share is expected to grow by 2.68% on average over the next years.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.39% on average per year.
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.32, which indicates a rather cheap valuation of IART.
Compared to the rest of the industry, the Price/Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 97.85% of the companies listed in the same industry.
IART is valuated cheaply when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
IART is valuated cheaply with a Price/Forward Earnings ratio of 5.26.
Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 99.46% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.46. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.32 | ||
| Fwd PE | 5.26 |
4.2 Price Multiples
IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 94.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.87 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.62
-0.04 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.55%
Inst Owner Change0%
Ins Owners3.07%
Ins Owner Change0.07%
Market Cap982.97M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (25.28%)
Short Float %9.95%
Short Ratio6.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)0%
PT rev (3m)-5.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.58%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-5.83%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.32 | ||
| Fwd PE | 5.26 | ||
| P/S | 0.6 | ||
| P/FCF | N/A | ||
| P/OCF | 11.01 | ||
| P/B | 0.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.87 |
EPS(TTM)2.37
EY18.78%
EPS(NY)2.4
Fwd EY19%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY9.09%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.25 |
F-Score5
WACC5.63%
ROIC/WACC0.76
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.61%
EBIT Next 3Y9.61%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.